Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Scientists create yellow potatoes with high carotenoid levels

Potatoes with higher levels of beneficial carotenoids are the result of U.S. Department of Agriculture (USDA) studies to improve one of America's most popular vegetables.

26 Oct 2012

Ophthotech announces data from Fovista Phase 2b trial on wet AMD

Ophthotech Corporation today announced that data from a large, prospective, randomized, controlled Phase 2b clinical trial of Ophthotech's Fovista anti-PDGF therapy (1.5 mg) in patients with neovascular age-related macular degeneration (wet AMD) will be presented during Retina Subspecialty Day at the American Academy of Ophthalmology Annual Meeting (AAO) on Sat., Nov. 10, 2012 at 9:15 a.m.

25 Oct 2012

Ranibizumab improves driving prospects for AMD patients

Treatment with ranibizumab can preserve and even improve the perceived driving ability of patients with age-related macular degeneration, show the results of two randomized trials.

10 Oct 2012

NACA could prevent or cure cataracts, macular degeneration and other eye conditions

Researchers at Missouri University of Science and Technology are working with an antioxidant that could prevent or cure cataracts, macular degeneration and other degenerative eye disorders.

10 Oct 2012

Ranibizumab injections keep those with AMD driving longer

The advanced neovascular, or “wet,” form of age-related macular degeneration (AMD), left untreated, is the most common cause of vision loss among the elderly and a leading reason for their loss of driving privileges. But results of a new study, published in the online version of the journal Ophthalmology, suggest that monthly injections of ranibizumab improve eye chart test results required for a driver’s license, build driver confidence and keep those with AMD driving longer.

3 Oct 2012

Experimental stem cell treatment improves vision in blind mice

An experimental treatment for blindness, developed from a patient's skin cells, improved the vision of blind mice in a study conducted by Columbia ophthalmologists and stem cell researchers.

3 Oct 2012

Galectin-1 drives growth of Kaposi sarcoma tumors

A sugar-loving protein drives the growth of Kaposi sarcoma (KS) tumors, according to a study published on October 1st in The Journal of Experimental Medicine. Interfering with these sugary interactions inhibited growth of Kaposi sarcomas in mice, hinting at the potential for new treatment strategies in humans.

2 Oct 2012

Level of vision, not gain in letters seen, marks success of AMD treatment

The number of patients with a particular level of vision may be a better mark of the success of treatment for neovascular age-related macular degeneration than the gain or loss of letters able to be seen in logMAR chart testing, suggest researchers.

1 Oct 2012

BioTime forms new wholly owned subsidiary

BioTime, Inc., an Alameda-based company engaged in research and development of innovative new products in the field of regenerative medicine utilizing stem cells and related technology, announced today that it has formed a new wholly owned subsidiary, BioTime Acquisition Corporation, to pursue opportunities and acquire assets and businesses in the fields of stem cells and regenerative medicine.

29 Sep 2012

Cost of glaucoma revealed

The first 6 months after an open-angle glaucoma diagnosis are the most costly within the first 2 years of having the condition, report US researchers.

26 Sep 2012

Ohr commences Phase II clinical trial of Squalamine for wet-AMD

Ohr Pharmaceutical today announced the initiation of a Phase II clinical trial to evaluate the efficacy and safety of Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration.

24 Sep 2012

Valeant purchases QLT’s Visudyne

Valeant Pharmaceuticals International, Inc. announced today that it has acquired Visudyne, used to treat abnormal growth of leaky blood vessels in the eye caused by wet age-related macular degeneration, from QLT Inc.

24 Sep 2012

Weill Cornell to purchase innovative equipment to help detect and treat diabetic retinopathy

Weill Cornell Medical College's ophthalmology services for diabetic patients received a boost last month, courtesy of a grant from the New York City Council secured by Councilwoman Jessica Lappin.

21 Sep 2012

Cedars-Sinai symposium to discuss latest findings on stem cell treatments for diabetes, eye diseases

Leading scientists and clinicians from across the nation will discuss the latest findings on potential stem cell treatments for diabetes and eye diseases at the second Cedars-Sinai Regenerative Medicine Scientific Symposium.

18 Sep 2012

Joslin Diabetes Center, Mass. Eye and Ear partner to form clinical and research alliance

Massachusetts Eye and Ear and the Joslin Diabetes Center announced today that they have reached agreement to form a clinical and research alliance, aimed toward providing coordinated high quality care to eye patients throughout greater Boston, especially those with or at-risk for diabetes-related eye disease.

11 Sep 2012

Combining two drugs may offer new and potent punch against cancer and other diseases

A new study by researchers at Weill Cornell Medical College shows combining two already-FDA approved drugs may offer a new and potent punch against diseases in which blood vessel growth is abnormal -- such as cancer, diabetic retinopathy, macular degeneration and rheumatoid arthritis.

11 Sep 2012

New method simplifies pharmaceutical production of proteins

Engineering researchers at the University of Arkansas have developed a method to simplify the pharmaceutical production of proteins used in drugs that treat a variety of diseases and health conditions, including diabetes, cancer, arthritis and macular degeneration.

29 Aug 2012

Vision symptoms plus retinal changes trigger need for AMD intervention

An analysis of over 1000 individuals presenting with suspected exudative age-related macular degeneration has revealed which factors are most predictive of the need for treatment.

22 Aug 2012

Molecular Partners, Allergan to develop and commercialize DARPins against ophthalmic diseases

Allergan, Inc. and Molecular Partners AG today announced that they have significantly expanded their existing relationship by entering into two separate agreements to discover, develop, and commercialize proprietary therapeutic DARPin products for the treatment of serious ophthalmic diseases.

21 Aug 2012

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

Genentech, a member of the Roche Group, today announced that Lucentis (ranibizumab injection) was approved by the U.S. Food & Drug Administration (FDA) for treatment of diabetic macular edema (DME), an eye condition in people with diabetes that causes blurred vision, severe vision loss and sometimes blindness

12 Aug 2012

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Scientists create yellow potatoes with high carotenoid levels

Ophthotech announces data from Fovista Phase 2b trial on wet AMD

Ranibizumab improves driving prospects for AMD patients

NACA could prevent or cure cataracts, macular degeneration and other eye conditions

Ranibizumab injections keep those with AMD driving longer

Experimental stem cell treatment improves vision in blind mice

Galectin-1 drives growth of Kaposi sarcoma tumors

Level of vision, not gain in letters seen, marks success of AMD treatment

BioTime forms new wholly owned subsidiary

Cost of glaucoma revealed

Ohr commences Phase II clinical trial of Squalamine for wet-AMD

Valeant purchases QLT’s Visudyne

Weill Cornell to purchase innovative equipment to help detect and treat diabetic retinopathy

Cedars-Sinai symposium to discuss latest findings on stem cell treatments for diabetes, eye diseases

Joslin Diabetes Center, Mass. Eye and Ear partner to form clinical and research alliance

Combining two drugs may offer new and potent punch against cancer and other diseases

New method simplifies pharmaceutical production of proteins

Vision symptoms plus retinal changes trigger need for AMD intervention

Molecular Partners, Allergan to develop and commercialize DARPins against ophthalmic diseases

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Newsletters you may be interested in